Hydroxyethylamine derivatives as HIV-1 protease inhibitors: a predictive QSAR modelling study based on Monte Carlo optimization

References

• M.D. Sepkowitz, AIDS–the first 20 years, N. Engl. J. Med. 344 (2001), pp. 1764–1772.
   PubMed Web of Science ®Google Scholar
• R.C. Gallo and L. Montagnier, The discovery of HIV as the cause of AIDS, N. Engl. J. Med. 349 (2003), pp. 2283–2285.
   PubMed Web of Science ®Google Scholar
• M. Lenassi, G. Cagney, M. Liao, T. Vaupotic, K. Bartholomeeusen, Y. Cheng, N.J. Krogan, A. Plemenitas, and B.M. Peterlin, HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells, Traffic 11 (2010), pp. 110–122.
   PubMed Web of Science ®Google Scholar
• P.B. Gilbert, I.W. McKeague, G. Eisen, C. Mullins, A. Gueve-NDiave, S. Mboup, and P.J. Kanki, Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal, Stat. Med. 22 (2003), pp. 573–593.
   PubMed Web of Science ®Google Scholar
• F. Yu, Y. Hao, H. Zhao, J. Xiao, N. Han, Y. Zhang, G. Dai, X. Chong, H. Zeng, and F. Zhang, Distinct mitochondrial disturbance in CD4+T and CD8+T cells from HIV-infected patients, J. Acquir. Immune Defic. Syndr. 74 (2017), pp. 206–212.
   PubMed Web of Science ®Google Scholar
• D.C. Douek, M. Roederer, and R.A. Koup, Emerging concepts in the immunopathogenesis of AIDS, Annu. Rev. Med. 60 (2009), pp. 471–484.
   PubMed Web of Science ®Google Scholar
• A.R. Lifson, Do alternate modes for transmission of human immunodeficiency virus exist? A review, JAMA 259 (1988), pp. 1353–1356.
   PubMed Web of Science ®Google Scholar
• S. Gayen, B. Debnath, S. Samanta, and T. Jha, QSAR study on some anti-HIV HEPT analogues using physicochemical and topological parameters, Bioorg. Med. Chem. 15 (2004), pp. 1493–1503.
   Google Scholar
• B. Gazzard and G. Moyle, revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee, Lancet 352(1998) (1998), pp. 314–316.
   PubMedGoogle Scholar
• C.J. Carpenter, M.A. Fischl, S.M. Hammer, M.S. Hirsch, D.M. Jacobsen, D.A. Katzenstein, J.S. Montaner, D.D. Richman, M.S. Saag, R.T. Schooley, M.A. Thompson, S. Vella, P.G. Yeni, and P.A. Volberding, Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel, JAMA 280 (1998), pp. 78–86.
   PubMed Web of Science ®Google Scholar
• A.R. Pazare, Evolution of anti-retroviral therapy: Multiple pills to fixed drug combinations, J. Assoc. Physicians India. 63 (2015), pp. 11–13.
   PubMedGoogle Scholar
• C.T. Su, W.L. Ling, W.H. Lua, Y.X. Haw, and S.K. Gan, Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: An implication of protease inhibitor cross-resistance, BMC Bioinformatics 17 (2016), p. 500.
   PubMed Web of Science ®Google Scholar
• M.C. Graves, J.J. Lim, E.P. Heimer, and R.A. Kramer, An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity, Proc. Natl. Acad. Sci. USA 85 (1988), pp. 2449–2453.
   PubMed Web of Science ®Google Scholar
• S.F. Le Grice, J. Mills, and J. Mous, Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation, EMBO J. 7 (1988), pp. 2547–2553.
   PubMed Web of Science ®Google Scholar
• N.E. Kohl, E.A. Emini, W.A. Schleif, L.J. Davis, J.C. Heimbach, R.A. Dixon, E.M. Scolnick, and I.S. Sigal, Active human immunodeficiency virus protease is required for viral infectivity, Proc. Natl. Acad. Sci. USA 85 (1988), pp. 4686–4690.
   PubMed Web of Science ®Google Scholar
• S.M. Hammer, J.J. Eron Jr, P. Reiss, R.T. Schooley, M.A. Thompson, S. Walmsley, P. Cahn, M.A. Fischl, J.M. Gatell, M.S. Hirsch, D.M. Jacobsen, J.S. Montaner, D.D. Richman, P.G. Yeni, and P.A. Volberding, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel, JAMA 300 (2008), pp. 555–570.
   PubMed Web of Science ®Google Scholar
• M.K. Parai, D.J. Huggins, H. Cao, M.N.L. Nalam, A. Ali, C.A. Schiffer, B. Tidor, and T.M. Rana, Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance, J. Med. Chem. 55 (2012), pp. 6328–6341.
   PubMed Web of Science ®Google Scholar
• A. Ali, G.S.K. Reddy, M.N.L. Nalam, S.G. Anjum, H. Cao, C.A. Schiffer, and T.M. Rana, Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones, J. Med. Chem. 53 (2010), pp. 7699–7708.
   PubMed Web of Science ®Google Scholar
• M.D. Altman, A. Ali, G.S.K. Reddy, M.N.L. Nalam, S.G. Anjum, H. Cao, S. Chellappan, V. Kairys, M.X. Fernandes, M.K. Gilson, C.A. Schiffer, T.M. Rana, and B. Tidor, HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants, J. Am. Chem. Soc. 130 (2008), pp. 6099–6113.
   PubMed Web of Science ®Google Scholar
• G.S.K. Reddy, A. Ali, M.N.L. Nalam, S.G. Anjum, H. Cao, R.S. Nathans, C.A. Schiffer, and T.M. Rana, Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2′ ligands in pseudosymmetric dipeptide isosteres, J. Med. Chem. 50 (2007), pp. 4316–4328.
   PubMed Web of Science ®Google Scholar
• A. Ali, G.S. Reddy, H. Cao, S.G. Anjum, M.N. Nalam, C.A. Schiffer, and T.M. Rana, Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands, J. Med. Chem. 49 (2006), pp. 7342–7356.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, An integrated ligand-based modelling approach to explore the structure-property relationships of influenza endonuclease inhibitors, Struct. Chem. (2017), in press. doi: 10.1007/s11224-017-0933-z.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, S. Bhargava, N. Adhikari, S. Gayen, and T. Jha, Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modeling techniques, J. Biomol. Struct. Dyn. (2017), in press. doi: 10.1080/07391102.2017.1288659.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi- QSAR analysis against Huntington's disease: A proposal to chemists!, Bioorg. Med. Chem. Lett. 26 (2016), pp. 5712–5718.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, Insight into the structural requirements of theophylline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors through multi-QSAR modelling and molecular docking approaches, Curr. Drug Descov. Tech. 13 (2016), pp. 84–100.
   PubMedGoogle Scholar
• S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, Exploring structural requirements of unconventional Knoevenagel-type indole derivatives as anticancer agents through comparative QSAR modelling approaches, Can. J. Chem. 94 (2016), pp. 637–644.
   Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, E. Benfenati, G. Gini, D. Leszczynska, and J. Leszczynski, CORAL: QSPR models for solubility of [C60] and [C70] fullerene derivatives, Mol. Divers. 15 (2011), pp. 249–256.
   PubMed Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, E. Benfenati, and G. Gini, QSAR modelling toxicity toward rats of inorganic substances by means of CORAL, Cent. Eur. J. Chem. 9 (2011), pp. 75–85.
   Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, R.G. Diaza, E. Benfenati, and G. Gini, Analysis of the co-evolutions of correlations as a tool for QSAR-modeling of carcinogenicity: An unexpected good prediction based on a model that seems untrustworthy, Cent. Eur. J. Chem. 9 (2011), pp. 165–174.
   Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, E. Benfenati, G. Gini, D. Leszczynska, and J. Leszczynski, QSAR modeling of anxiolytic activity taking into account the presence of keto- and enol-tautomers by balance of correlations with ideal slopes, Cent. Eur. J. Chem. 9 (2011), pp. 846–854.
   Google Scholar
• Chem 3D Pro Version 8.0 and Chem Draw Ultra Version 8.0, software programs developed by Cambridge Soft Corporation, USA, 2015; software available at http://www.cambridgesoft.com.
   Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors, J. Mol. Struct. 1143 (2017), pp. 49–64.
   Web of Science ®Google Scholar
• A.K. Halder, S.A. Amin, T. Jha, and S. Gayen, Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches, SAR QSAR Environ. Res. 28 (2017), pp. 253–273.
   PubMed Web of Science ®Google Scholar
• M. Awasthi, S.A. Amin, V. Shukla, S. Jain, U.K. Patil, and S. Gayen, Structural requirements of some derivatives based on natural alkaloid lycorine for their dengue inhibitory activity to accelerate dengue drug discovery efforts, Indian J. Nat. Prod. Res. 7 (2016), pp. 221–228.
   Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, Designing potential antitrypanosomal thiazol-2-ethylamines through predictive regression based and classification based QSAR analyses, Curr. Drug Discov. Tech. 14 (2017), pp. 39–52.
   PubMedGoogle Scholar
• CORAL software, IRCCS, Milan, Italy, 2017; available at: http://www.insilico.eu/CORAL/.
   Google Scholar
• L.M.A. Mullen, P.R. Duchowicz, and E.A. Castro, QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents, Chemometr. Intell Lab. 107 (2011), pp. 269–275.
   Web of Science ®Google Scholar
• A. Kumar and S. Chauhan, Monte Carlo method based QSAR modelling of natural lipase inhibitors using hybrid optimal descriptors, SAR QSAR Environ. Res. 28 (2017), pp. 179–197.
   PubMed Web of Science ®Google Scholar
• V. Prachayasittikul, A. Worachartcheewan, A.P. Toropova, A.A. Toropov, N. Schaduangrat, V. Prachayasittikul, and C. Nantasenamat, Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors, SAR QSAR Environ. Res. 28 (2017), pp. 1–16.
   PubMed Web of Science ®Google Scholar
• J.B. Veselinovic, G.M. Nikolic, N.V. Trutic, J.V. Zivkovic, and A.M. Veselinovic, Monte Carlo QSAR models for predicting organophosphate inhibition of acetylcholinesterase, SAR QSAR Environ. Res. 26 (2015), pp. 449–460.
   PubMed Web of Science ®Google Scholar
• S. Begum and P.G.R. Achary, Simplified molecular input line entry system-based: QSAR modelling for MAP kinase-interacting protein kinase (MNK1), SAR QSAR Environ. Res. 26 (2015), pp. 343–361.
   PubMed Web of Science ®Google Scholar
• P.G.R. Achary, Simplified molecular input line entry system-based optimal descriptors: QSAR modelling for voltage-gated potassium channel subunit Kv7.2, SAR QSAR Environ. Res. 25 (2014), pp. 73–90.
   PubMed Web of Science ®Google Scholar
• N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison, Open babel: An open chemical toolbox, J. Cheminform. 33 (2011), pp. 33.
   Google Scholar
• A.A. Toropov, A.P. Toropova, and E. Benfenati, SMILES-based optimal descriptors: QSAR modeling of carcinogenicity by balance of correlations with ideal slopes, Eur. J. Med. Chem. 45 (2010), pp. 3581–3587.
   PubMed Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, and E. Benfenati, A quasi-QSPR modelling for the photocatalytic decolourization rate constants and cellular viability (CV%) of nanoparticles by CORAL, SAR QSAR Environ. Res. 26 (2015), pp. 29–40.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, A.P. Toropova, and E. Benfenati, QSPR modeling for enthalpies of formation of organometallic compounds by means of SMILES-based optimal descriptors, Chem. Phys. Lett. 461 (2008), pp. 343–347.
   Web of Science ®Google Scholar
• P. Ambure and K. Roy, Understanding the structural requirements of cyclic sulfone hydroxyethylamines as hBACE1 inhibitors against Aβ plaques in Alzheimer's disease: A predictive QSAR approach, RSC Adv. 6 (2016), pp. 28171–28186.
   Web of Science ®Google Scholar
• K. Roy, R.N. Das, P. Ambure, and R.B. Aher, Be aware of error measures: Further studies on validation of predictive QSAR models, Chemom. Intell. Lab. Syst. 152 (2016), pp. 18–33.
   Web of Science ®Google Scholar
• XternalValidationPlus v1.2, Jadavpur University, Kolkata, 2016; available at: http://teqip.jdvu.ac.in/QSAR_Tools/
   Google Scholar
• T.I. Netzeva, A.P. Worth, T. Aldenberg, R. Benjamin, M.T.D. Cronin, P. Gramatica, J.S. Jaworska, S. Kahn, G. Klopman, C.A. Marchant, G. Myatt, N. Nikolova-Jeliazkova, G.Y. Patlewicz, R. Perkins, D.W. Roberts, T.W. Schultz, D.T. Stanton, J.J.M. van de Sandt, W. Tong, G. Veith, and C. Yang, Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52, Altern. Lab. Anim. 33 (2005), pp. 155–173.
   PubMed Web of Science ®Google Scholar
• K. Roy, S. Kar, and P. Ambure, On a simple approach for determining applicability domain of QSAR models, Chemom. Intell. Lab. Syst. 145 (2015), pp. 22–29.
   Web of Science ®Google Scholar
• M.A. Islam and T.S. Pillay, Simplified molecular input line entry system-based descriptors in QSAR modeling for HIV-protease inhibitors, Chemometr. Intell. Lab. Syst. 153 (2016), pp. 67–74.
   Web of Science ®Google Scholar
• A.P. Toropova, A.A. Toropov, J.B. Veselinović, F.N. Miljković, and A.M. Veselinović, QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method, Eur. J. Med. Chem. 77 (2014), pp. 298–305.
   PubMed Web of Science ®Google Scholar
• R.F. Alamdari, A. Mani-Varnosfaderani, M. Asadollahi-Baboli, and A. Khalafi-Nezhad, Monte Carlo sampling and multivariate adaptive regression splines as tools for QSAR modelling of HIV-1 reverse transcriptase inhibitors, SAR QSAR Env. Res. 23 (2012), pp. 665–682.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, A.P. Toropova, I. Raska Jr, E. Benfenati, and G. Gini, Development of QSAR models for predicting anti-HIV-1 activity using the Monte Carlo method, Cent. Eur. J. Chem. 11 (2013), pp. 371–380.
   Google Scholar
• J. Veselinović, A. Veselinović, A. Toropov, A. Toropova, I. Damnjanović, and G. Nikolić, Monte Carlo method based QSAR modeling of coumarin derivates as potent HIV-1 integrase inhibitors and molecular docking studies of selected 4-phenyl hydroxycoumarins, Acta Fac. Medicae Naissensis 31 (2014), pp. 95–103.
   Google Scholar
• A.K. Halder and T. Jha, Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity, Bioorganic Med. Chem. Lett. 20 (2010), pp. 6082–6087.
   PubMed Web of Science ®Google Scholar
• M.H. Fatemi, A. Heidari, and S. Gharaghani, QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors, J. Theor. Biol. 369 (2015), pp. 13–22.
   PubMed Web of Science ®Google Scholar